Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Colorado for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Colorado only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Colorado (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

John Burke (NPI 1801871215)

Field	Value
Entity Type	Individual
Organization	John Burke
Address	1700 S Potomac St
City	Aurora
State	CO
ZIP	80012
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	December 8, 2005

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: total Medicare revenue is $2.6M and there is no Medicaid billing on file, so the practice’s public‑payer footprint and financial scale are driven entirely by Medicare reimbursements. The NPI was enumerated on 2005-12-08 (≈21 years ago), indicating a long-established Medicare presence rather than a recent entrant to the program.

Revenue is highly concentrated in a small set of drugs and infusion services: the precomputed top 3 Medicare codes by revenue account for 77.5% of this provider’s total Medicare revenue. Those top contributors are J9144 ($957.6K, 38.5% of Medicare revenue), J9271 ($645K, 25.9%), and J1568 ($323.7K, 13.0%), so a few high‑cost injectable therapies dominate income.

The code mix and volumes point to an infusion‑based hematology/oncology practice. J9144 (daratumumab) has 25.2K claims with $38 avg paid/claim and J9271 (pembrolizumab) has 15K claims with $43 avg paid/claim, and there are substantial chemotherapy administration codes (e.g., 96413 with 516 claims and $104 avg paid/claim), all consistent with ongoing outpatient infusion treatment for hematologic malignancies and oncology indications.

On competitive standing, the provider is a high‑volume national participant for certain monoclonal antibody therapies. J9144 ranks #28 of 615 providers nationally (96th percentile) and is described as "notably above typical national volume for this code," while J1568 ranks #31 of 381 (92th percentile) and J9271 ranks #686 of 1841 (62th percentile), both characterized as typical or unremarkable volumes in their peer groups.

Operational throughput evidence: high volumes of basic lab and access services support frequent infusion visits and monitoring. Codes such as 36415 (2.5K claims, $8 avg paid/claim; ranks #698 of 86467, 99th percentile), 85025 (2.9K claims, $8 avg paid/claim; ranks #610 of 32833, 98th percentile), and 80053 (1.9K claims, $10 avg paid/claim; ranks #652 of 26416, 98th percentile) indicate substantial on‑site phlebotomy and routine lab work that typically accompany a busy infusion practice.

The practice also bills for enhanced oncology services and moderate complexity outpatient care, suggesting care management capabilities tied to infusion oncology. M0010 shows 276 claims at $71 avg paid/claim ($19.6K revenue) and ranks #27 of 544 (95th percentile), while 99214 has 658 claims ($95 avg paid/claim, $62.5K revenue) and ranks #29722 of 479517 (94th percentile), reflecting frequent moderate‑complexity office encounters alongside infusion services.

There is a mix of branded biologics, biosimilars, and supportive agents in the revenue mix that shapes drug procurement and margin considerations. The practice uses biosimilar rituximab (Q5119, 3.8K claims, $22 avg paid/claim; ranks #28 of 335, 92th percentile) alongside originator or other biologics such as J9144 and J9271, and supportive agents like J2506 (pegfilgrastim) and J1437 (ferric derisomaltose) appear at lower relative rank and revenue share.

From a payer / market risk perspective, reliance on a concentrated set of high‑cost injectable therapies means reimbursement or utilization changes for a few codes could materially affect revenues; the top three codes alone drive the majority of Medicare revenue (77.5%). Given the absence of Medicaid billing, shifts in Medicare policy or utilization for these key oncology infusions would have outsized impact on this provider’s publicly reported revenue.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

88 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9144	Injection, daratumumab, 10 mg and hyaluronidase‑fihj	25,200	$40	$957.6K
J9271	Injection, pembrolizumab, 1 mg	15,000	$40	$645K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	9,810	$30	$323.7K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	3,790	$20	$83.4K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	660	$100	$62.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	520	$100	$53.7K
J2506	Injection, pegfilgrastim, excludes biosimilar, 0.5 mg	320	$90	$30.5K
J0897	Injection, denosumab, 1 mg	1,560	$20	$28.1K
82784	The lab analyst performs the technical lab test to analyze the concentration of a particular gamma globulin in the specimen. The analyst may test for immunoglobulin A, immunoglobulin D,…	2,990	$10	$26.9K
88185	The lab analyst performs the technical component of a flow cytometry procedure using cell surface, cytoplasmic, or nuclear markers to characterize cells and aid clinicians in diagnosing patients with…	1,230	$20	$24.6K

Showing 1–10 of 88

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 88 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Colorado Distribution

John Burke — 14 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Colorado

Full comparison — all codes billed, vs. state median

88 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	7	40	10,700	$40	$520.5K
J9144	2	20	7,560	$40	$354.8K
J1568	2	30	2,240	$30	$101.5K
J0897	104	140	2,580	$20	$68.8K
Q5119	1	10	1,960	$20	$47.4K
J2506	4	10	370	$90	$32.3K
J0881	7	10	7,670	$1	$23.4K
J3490	7	60	50	$290	$23.1K
J1437	3	10	1,400	$20	$22.7K
96413	7	140	130	$100	$19.7K

Showing 1–10 of 88

Related Providers

Other providers that share a Tax Identification Number (TIN) with John Burke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Nauman Moazzam	CO	Hematology & Oncology Physician	$3.6M	$0
Robert Rifkin	CO	Hematology & Oncology Physician	$3.3M	$0
Ioana Hinshaw	CO	Hematology & Oncology Physician	$2.7M	$0
Patrick Eulitt	CO	Medical Oncology Physician	$2.4M	$0
Patrick Richard	CO	Radiation Oncology Physician	$1.9M	$0
Christopher Benton	CO	Hematology & Oncology Physician	$1.8M	$0
Paul Decarolis	CO	Hematology & Oncology Physician	$1.6M	$0
Maurice Markus	CO	Hematology & Oncology Physician	$1.6M	$0
Sujatha Nallapareddy	CO	Hematology & Oncology Physician	$1.4M	$0
Manojkumar Bupathi	CO	Hematology & Oncology Physician	$1.4M	$0

Nearby Providers

Other providers in the same ZIP code as John Burke, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Continuum Of Colorado	CO	Community/Behavioral Health Agency	$0	$61.3M
Developmental Pathways Inc	CO	Case Management Agency	$0	$37.2M
Hca Healthone LLC	CO	General Acute Care Hospital	$0	$24.4M
Ahiska Homecare LLC	CO	In Home Supportive Care Agency	$0	$22.3M
Beacon Home Care	CO	In Home Supportive Care Agency	$0	$22.1M
Developmental Pathways, Inc.	CO	Day Training/Habilitation Specialist	$0	$20.6M
Global Intersections, Inc.	CO	Developmentally Disabled Services Day Training Agency	$0	$19.7M
Bmh Corp.,llc	CO	In Home Supportive Care Agency	$0	$18.2M
Hero Dental Of Aurora PC	CO	Dentist	$0	$14M
Hans Adult Day Care LLC	CO	Adult Day Care Clinic/Center	$0	$13.2M

John Burke — Billing Profile & Reimbursement Data

Sign up for John Burke — Billing Profile & Reimbursement Data policy alerts

John Burke — Billing Profile & Reimbursement Data

Sign up for John Burke — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References